Piper Sandler analyst Edward Tenthoff raised the firm’s price target on Alnylam (ALNY) to $489 from $449 and keeps an Overweight rating on the shares. The firm notes AMVUTTRA sales of $685M in Q3 beat Street consensus driven by doubling of U.S. ATTR-CM revenues to $300M. Alnylam raised TTR revenue guidance to $2.475B-$2.525B in 2025, and Piper projects AMVUTTRA could grow to $3.9B in 2026.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
- Alnylam price target raised to $527 from $460 at Barclays
- Alnylam price target raised to $475 from $400 at Chardan
- Alnylam Pharmaceuticals Reports Strong Q3 2025 Growth
- Alnylam Pharma’s Strong Financial Performance and Strategic Growth Initiatives Justify Buy Rating
- Alnylam Pharma’s Strong Q3 Performance and Promising Outlook Reinforce Buy Rating Despite Legal Concerns